Search Tag: Pfizer/BioNTech

Executive Health Management

2021 22 Dec

PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) is authorized for emergency use in both high-risk adults and high-risk pediatric patients 12 years of age and older weighing at least 40 kg EUA based on clinical data from EPIC-HR study, showing PAXLOVID reduced risk of hospitalization or death by 89% (within three days of symptom...Read more

Executive Health Management

2021 23 Sep

Today, 23 September, the US FDA amended the EUA for the Pfizer-BioNTech COVID-19 Vaccine to permit a booster dose for those who are 65 years and older, who are at risk for severe disease, and whose professions bring them occupational exposure. This booster dose can be administered at least six months after completion of the primary two-dose regimen....Read more

Executive Health Management

2021 21 Sep

Given that children and adolescents can get sick with COVID-19, attending K-12 schools in-person remains a risk. According to the American Academy of Pediatrics, children accounted for 25.7% of US cases for the week of 16 September (American Academy of Pediatrics, 2021), while hospitalisations averaged 311 children/day (Centers for Disease Control...Read more

Executive Health Management

2021 20 Apr

Over the last week the COVID-19 vaccine landscape has once again changed drastically, with the use of J&J’s Janssen suspended in many countries and new players attracting more attention.   You might also like: Shortages of COVID-19 vaccine supplies are being felt globally, not excluding the EU and the UK. Do companies fulfil their obligations...Read more

Executive Health Management

2021 29 Mar

Shortages of COVID-19 vaccine supplies are being felt globally, not excluding the EU and the UK. Do companies fulfil their obligations and where will new manufacturing facilities be created?   You might also like: Why has AstraZeneca’s COVID-19 vaccine been the centre of attention in Europe over the past few days? Learn more...Read more

Executive Health Management

2021 23 Jan

COVAX, the global initiative to ensure equitable access to COVID-19 vaccines across the world, has announced new agreements for Pfizer/BioNTech and AstraZeneca/Oxford vaccines delivery, about 200 million doses in total.   You might also like: COVID-19 Vaccines: Tracking and Future Distribution   Specifically,...Read more

Executive Health Management

2020 02 Dec

The UK, first in the world, authorises Pfizer COVID-19 vaccine and is looking into fast-tracking AstraZeneca’s. In the meantime, Pfizer and Moderna both file applications for their vaccines’ emergency use in the U.S. and Europe.   You might also like: Coronavirus, Tensegrity and CSR: Year of Living Dangerously   The...Read more